Real-world outcomes of adjuvant gemcitabine gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma

Real-world outcomes of adjuvant gemcitabine gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma

Background: Adjuvant chemotherapy is the standard treatment after curative-intent surgery for pancreatic ductal adenocarcinoma (PDAC). The phase-3 ESPAC-4 trial demonstrated significantly improved overall survival (OS) with Gemcitabine plus capecitabine (GemCap) over Gemcitabine (Gem) in Europe. We...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Sora Kang, Changhoon Yoo, So Heun Lee, Dongwook Oh, Tae Jun Song, Sang Soo Lee, Jae Ho Jeong, Do Hyun Park, Dong Wan Seo, Jin-hong Park, Dae Wook Hwang, Ki Byung Song, Jae Hoon Lee, Woohyung Lee, Bong Jun Kwak, Sarang Hong, Heung-Moon Chang, Baek-Yeol Ryoo, Kyu-pyo Kim, Song Cheol Kim
Formaat:	Artikel
Taal:	English
Gepubliceerd in:	SAGE Publishing 2022-05-01
Reeks:	Therapeutic Advances in Medical Oncology
Online toegang:	https://doi.org/10.1177/17588359221097190

Gelijkaardige items

Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis
door: Heejung Chae, et al.
Gepubliceerd in: (2020-05-01)

Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy
door: Kwang Hyun Chung, et al.
Gepubliceerd in: (2017-03-01)

Comparing the intra-tumoral distribution of Gemcitabine, 5-Fluorouracil, and Capecitabine in a murine model of pancreatic ductal adenocarcinoma.
door: Louise M Fanchon, et al.
Gepubliceerd in: (2020-01-01)

Comparison of Characteristics and Survival Rates of Resectable Pancreatic Ductal Adenocarcinoma according to Tumor Location
door: Min Kyu Sung, et al.
Gepubliceerd in: (2021-11-01)

Deep Vein Thrombosis as a Complication of Gemcitabine-Capecitabine Chemotherapy in Adenocarcinoma of Gallbladder
door: Widiasi ED, et al.
Gepubliceerd in: (2024-12-01)

89Zr-anti-γH2AX-TAT allows early monitoring of response to gemcitabine and capecitabine therapy in pancreatic ductal adenocarcinoma
door: Knight, J, et al.
Gepubliceerd in: (2016)

Advanced adrenocortical carcinoma successfully treated with gemcitabine plus capecitabine as second‐line chemotherapy
door: Akinaru Yamamoto, et al.
Gepubliceerd in: (2020-11-01)

Targeted Therapy of Hepatocellular Carcinoma Using Gemcitabine-Incorporated GPC3 Aptamer
door: Jun Young Park, et al.
Gepubliceerd in: (2020-10-01)

Overcoming Microbiome-Acquired Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma
door: Inês Mendes, et al.
Gepubliceerd in: (2024-01-01)

An Update on Gemcitabine-Based Chemosensitization Strategies in Pancreatic Ductal Adenocarcinoma
door: Tianpeng Zhang, et al.
Gepubliceerd in: (2023-12-01)

Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer
door: Jeung Eun Lee, et al.
Gepubliceerd in: (2020-01-01)

Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma
door: Zhou Zhu, et al.
Gepubliceerd in: (2023-10-01)

Inflammatory markers as prognostic indicators in pancreatic cancer patients who underwent gemcitabine-based palliative chemotherapy
door: Hong Jun Kim, et al.
Gepubliceerd in: (2020-01-01)

SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer
door: Myeong Jin Kim, et al.
Gepubliceerd in: (2023-10-01)

Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction
door: Da Eun Lee, et al.
Gepubliceerd in: (2022-08-01)

Combinatorial immunotherapy with gemcitabine and ex vivo-expanded NK cells induces anti-tumor effects in pancreatic cancer
door: Eun-Kyoung Koh, et al.
Gepubliceerd in: (2023-05-01)

Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma
door: Feng Shao, et al.
Gepubliceerd in: (2018-06-01)

Simultaneous Estimation of Gemcitabine Hydrochloride and Capecitabine Hydrochloride in Combined Tablet Dosage Form by RP-HPLC Method
door: V. Rajesh, et al.
Gepubliceerd in: (2011-01-01)

Editorial Comment to Advanced adrenocortical carcinoma successfully treated with gemcitabine plus capecitabine as second‐line chemotherapy
door: Shuya Kandori
Gepubliceerd in: (2020-11-01)

Clinical Outcome of RAMPS for Left-Sided Pancreatic Ductal Adenocarcinoma: A Comparison of Anterior RAMPS versus Posterior RAMPS for Patients without Periadrenal Infiltration
door: Jaewoo Kwon, et al.
Gepubliceerd in: (2021-09-01)

Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation.
door: Junjie Li, et al.
Gepubliceerd in: (2018-01-01)

Lipocalin2 promotes invasion, tumorigenicity and gemcitabine resistance in pancreatic ductal adenocarcinoma.
door: Lisa Leung, et al.
Gepubliceerd in: (2012-01-01)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
door: Jane E. Rogers, et al.
Gepubliceerd in: (2020-08-01)

Recent Advances in Lipid-Based Nanosystems for Gemcitabine and Gemcitabine–Combination Therapy
door: Saffiya Habib, et al.
Gepubliceerd in: (2021-02-01)

Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy
door: Salvatore Grisanti, et al.
Gepubliceerd in: (2021-02-01)

Cardiotoxicity caused by gemcitabine
door: Yuri Isaakyan, et al.
Gepubliceerd in: (2023-01-01)

Gemcitabine in Recurrent Meningioma
door: Satvik Khaddar, et al.
Gepubliceerd in: (2020-10-01)

Development of gemcitabine-modified miRNA mimics as cancer therapeutics for pancreatic ductal adenocarcinoma
door: John G. Yuen, et al.
Gepubliceerd in: (2024-03-01)

The synergism of Clinacanthus nutans Lindau extracts with gemcitabine: downregulation of anti-apoptotic markers in squamous pancreatic ductal adenocarcinoma
door: Ling-Wei Hii, et al.
Gepubliceerd in: (2019-09-01)

Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
door: Kazuma Sugimoto, et al.
Gepubliceerd in: (2022-11-01)

FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
door: Changhoon Yoo, et al.
Gepubliceerd in: (2020-09-01)

Gemcitabine-Incorporated G-Quadruplex Aptamer for Targeted Drug Delivery into Pancreas Cancer
door: Jun Young Park, et al.
Gepubliceerd in: (2018-09-01)

1-Palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol (PLAG) attenuates gemcitabine-induced neutrophil extravasation
door: Jinseon Jeong, et al.
Gepubliceerd in: (2019-01-01)

Comparison of adjuvant gemcitabine plus S-1 with S-1 monotherapy for pancreatic ductal adenocarcinoma: Retrospective real-world data
door: Hui Tang, et al.
Gepubliceerd in: (2022-12-01)

Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study
door: Haorui Li, et al.
Gepubliceerd in: (2023-10-01)

Circulating tumour cells as an indicator of early and systemic recurrence after surgical resection in pancreatic ductal adenocarcinoma
door: Yejong Park, et al.
Gepubliceerd in: (2021-01-01)

Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma
door: Ana Acuna-Villaorduna MD, et al.
Gepubliceerd in: (2022-10-01)

LncRNA TUG1 promoted viability and associated with gemcitabine resistant in pancreatic ductal adenocarcinoma
door: Fan Yang, et al.
Gepubliceerd in: (2018-06-01)

Real-World Outcomes of Gemcitabine, Cisplatin, and Nab-Paclitaxel Chemotherapy Regimen for Advanced Biliary Tract Cancer: A Propensity Score-Matched Analysis
door: Kwangrok Jung, et al.
Gepubliceerd in: (2022-09-01)

A case of gemcitabine-induced thrombotic microangiopathy in a urothelial tumor patient with a single kidney
door: Hyunjin Ryu, et al.
Gepubliceerd in: (2015-12-01)